Tagged with HIV

Global First established in 1985 at the height of the AIDS pandemic, IAPAC is the world’s oldest medical association dedicated to HIV. Today, the organisation brings together over 30,000 professional and paraprofessionals delivering services to people living with and affected by the disease. In an exclusive and wide-ranging interview, IAPAC President…

Global AVAC is a global advocacy group focused on HIV prevention. It aims to accelerate ethical research and effective deployment of HIV prevention tools while working to ensure their equitable access. In an exclusive PharmaBoardroom interview, AVAC Executive Director Mitchell Warren looks back on the terrific advances that HIV science has…

Global After positions at Novartis and Merck, Bettina Bauer, a trained scientist, joined Gilead in 2019 as VP and general manager of its German affiliate. Today, as the VP of the company’s global commercial strategy and operations for HIV, COVID-19, and emerging viruses, she discusses the company’s strides in HIV prevention…

Hong Kong Based at Gilead Sciences’ Hong Kong hub, as VP & GM of Asia, Turkey, and the Middle East, American Dustin Haines oversees a vast region that includes the “Asia 5” territories Singapore, Malaysia, Taiwan, Hong Kong and South Korea and is the biggest of the company’s intercontinental areas with respect…

UAE 16-year Gilead veteran, Vítor Papão, recently left Europe to take on a new role within the company as general manager of the vast Middle East & Russia cluster. He discusses the particularities of the region, and the partnerships and initiatives Gilead is actively pursuing with local stakeholders.   We have…

Africa The third and final piece in Lenias Hwenda of Medicines for Africa’s series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come (read part one here and part two here). Here, Hwenda examines the persistent challenge of HIV/AIDS…

Africa The second in a three-part series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come (read part one here) from Lenias Hwenda of Medicines for Africa. Here, Hwenda shines a light on the importance of preventing mother-to-child transmission…

Africa In the first of a series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come, Lenias Hwenda of Medicines for Africa shares her personal meditations on the HIV pandemic, the impact of expanded access to antiretroviral therapy, and…

Africa While HIV has shifted from a death sentence to a manageable disease in most developed nations, there are several reasons why it still represents a huge global issue. It remains highly infectious and difficult to detect in the early stages of infection, while existing treatments are unavailable or too expensive…

Global The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and middle-income countries (LMICs), found in this year’s edition that the 20 companies surveyed have firmly responded to access issues exposed by COVID-19. GSK remains at the…

Global In only 21 years, the Global Fund has made remarkable progress in the fight to eliminate HIV, tuberculosis (TB), and malaria across the world, contributing to 44 million lives saved. Cross-sectoral partnerships that leverage the skills and capabilities of governments, multilateral agencies, bilateral partners, civil society groups, people affected by…

Global With several COVID-19 vaccines gaining regulatory approval across the world in record time, a spotlight has been shone on the vaccines field more widely, notably the 30-year wait for a HIV vaccine. Janssen Global Therapeutic Area Head of Vaccines Johan Van Hoof recently sat down with PharmaBoardroom to discuss the…